Ken-Ichi Fujita

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Metastatic Colorectal Cancer

Clinical Evaluation

Small Cell Lung Cancer

Top Venues

Cancer chemotherapy and pharmacology

BMC pulmonary medicine

Drug metabolism and disposition: the biological fate of chemicals

European journal of breast health

This page only lists publications with an associated author ORCID identifier.

Publications

Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Ken-Ichi Fujita
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer. Cancer chemotherapy and pharmacology 94 (1) (2024)
Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Ken-Ichi Fujita
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer. Cancer chemotherapy and pharmacology (2024)
Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Ken-Ichi Fujita
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer. Cancer chemotherapy and pharmacology 94 (1) (2024)
Yang Li, Yasuhiro Kazuki, Thomas Drabison, Kaoru Kobayashi, Ken-Ichi Fujita, Yue Xu, Yan Jin, Eman Ahmed, Junan Li, Eric D Eisenmann, Sharyn D Baker, Guido Cavaletti, Alex Sparreboom, Shuiying Hu
Vincristine Disposition and Neurotoxicity are Unchanged in Humanized CYP3A5 Mice . Drug metabolism and disposition: the biological fate of chemicals (2023)
Yukitaka Shibata, Natsumi Matsumoto, Remi Murase, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Ken-Ichi Fujita
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer. Cancer chemotherapy and pharmacology (2023)
Ken-Ichi Fujita, Natsumi Matsumoto, Remi Murase, Kosuke Takeshima, Hiroo Ishida, Yutaro Kubota
Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancer. Clinical and translational science (2023)
Yuta Nio, Hiroo Ishida, Natsumi Matsumoto, Sojiro Kusumoto, Yutaro Kubota, Takuya Tsunoda, Yasutsuna Sasaki, Ken-Ichi Fujita
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. BMC pulmonary medicine 22 (1) (2022)
Fuka Takada, Hiromi Okuyama, Seigo Nakamura, Ken-Ichi Fujita
Application of Personal Health Record in Enhancing the Quality of Life in Patients With Breast Cancer Who Received Adjuvant Hormonal Therapy. European journal of breast health 18 (2) (2022)
Ayako Tsuboya, Yutaro Kubota, Hiroo Ishida, Ryotaro Ohkuma, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Takuya Tsunoda, Yasutsuna Sasaki, Natsumi Matsumoto, Yusuke Kondo, Yukana Tomoda, Hiroyuki Kusuhara, Ken-Ichi Fujita
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure. Cancer chemotherapy and pharmacology 88 (3) (2021)
Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Masae Sekido, Ryotaro Ohkuma, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Takuya Tsunoda, Toshikazu Ikusue, Kouji Kobayashi, Atsushi Hisamatsu, Hirokazu Toshima, Ken Shimada, Ken-Ichi Fujita
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients. Cancer chemotherapy and pharmacology 85 (6) (2020)